Insulin resistance: Focus on the adipose tissue;Inzulinrezisztencia - Középpontban a zsírszövet

Lege Artis Medicinae

Volumn 14, Issue 3, 2004, Pages 171-178

  Elemér, Urich ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adipocyte hypertrophy and hyperplasia; Insulin resistance; Metabolic syndrome; Obesity; PPAR ; Thiazolidinedione; Type 2 diabetes; Visceral and subcutaneous adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADIPOCYTE; ADIPOSE TISSUE; CELL HYPERPLASIA; DRUG EFFICACY; HUMAN; HYPERTROPHY; INSULIN RESISTANCE; INSULIN RESPONSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SUBCUTANEOUS FAT;

EID: 1842765618     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Hinsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939;4:119-52.
2. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237(3):E214-23.
3. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
4. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21(12):2191-2.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607.
6. Hidvégi T, Jermendy Gy. Az X-syndromától a metabolikus syndromáig. Magyar Alapeflátási Archivum 4(1):17-32.
7. Magyar Diabetes Társaság Metabolikus Munkacsoportja. A metabolikus szindróma definíciója, diagnosztikai kritériumrendszere és szurése. Orvosi Hetilap 2002;143:785-8.
8. Neel JV: Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962;14:353-62.
9. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. Obes Rev 2001;2(4):239-54.
10. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003;14(3):137-45.
11. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32(Suppl 3):14-23.
12. Arner P. Free fatty acids - do they play a central role in type 2 diabetes? Diabetes Obes Metab 2001;3(Suppl 1):S11-9.
13. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;13;1:785-9.
14. Beltowski J. Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit 2003;9(2):RA55-61.
15. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13(1):18-23.
16. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956;4(1):20-34.
17. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, Potter JD, et al. Body fat distribution and 5-year risk of death in older women. JAMA 1993;269(4):483-7.
18. Fontbonne A, Thibult N, Eschwege E, Ducimetiere P. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance of diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 1992;35(5):464-8.
19. Kalmijn S, Curb JD, Rodriguez BL, Yano K, Abbott RD. The association of body weight and anthropometry with mortality in elderly men: the Honolulu Heart Program. Int J Obes Relat Metab Disord 1999;23(4):395-402.
20. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45(5):633-8.
21. Frayn KN. Visceral fat and insulin resistance - causative or correlative? Br J Nutr 2000;83(Suppl 1):S71-7.
22. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96(1):88-98.
23. Abate N, Garg A, Coleman R, Grundy SM, Peshock RM. Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am J Clin Nutr 1997; 65(2):403-8.
24. Thomas EL, Saeed N, Hajnal JV, Brynes A, Goldstone AP, Frost G, et al. Magnetic resonance imaging of total body fat. J Appl Physiol 1998;85(5):1778-85.
25. Peiris AN, Hennes MI, Evans DJ, Wilson CR, Lee MB, Kissebah AH. Relationship of anthropometric measurements of body fat distribution to metabolic profile in premenopausal women. Acta Med Scand Suppl 1988;723:179-88.
26. Fujioka S, Matsuzawa Y, Tokunaga K, Kawamoto T, Kobatake T, Keno Y, et al. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes 1997;15(12):853-9.
27. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003;24(6):276-83.
28. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999;48(8):1586-92.
29. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999;48(1):94-8.
30. Seidell JC, Bouchard C. Visceral fat in relation to health: is it a major culprit or simply an innocent bystander? International Journey of Obesity 1997;21:626-31.
31. Salans LB, Knittle JL, Hirsch J. Role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Invest 1968;47:153-65.
32. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36.
33. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000;43(12):1498-506.
34. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002;967:363-78.
35. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev 1998;12(20):3168-81.
36. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105(3):271-8.
37. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 2000;26(1):13.
38. Camp HS, Ren D, Leff T Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med 2002;8(9):442-7.
39. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34(3):217-24.
40. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16(3):179-92.
41. Jermendy Gy, Csermely P. Tiazolidindionok - az orális antidiabetikumok új hatástani csoportja. Orvosi Hetilap 2001;142(29):1547-54.
42. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35.
43. Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002;22(1):1-23.
44. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 2002;10(10):1008-15.
45. Collins AR. Pleiotropic vascular effects of PPARgamma ligands. Drug News Perspect 2003;16(4):197-204.
46. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PRAR) in atherosclerosis. Biochem Pharmacol 2000;60(8):1245-50.